CAS 850649-62-6
:Benzoato di alogliptina
- 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile benzoate
- Alogliptin Benzoate
- Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, benzoate (1:1)
- Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, monobenzoate
- Nesina
- Syr-322
Alogliptin
CAS:Formula:C18H21N5O2Purezza:≥ 98.0%Colore e forma:White to off-white powderPeso molecolare:339.39Alogliptin Benzoate
CAS:Formula:C18H21N5O2·C7H6O2Colore e forma:White To Off-White SolidPeso molecolare:339.40 122.12Alogliptin Benzoate
CAS:Alogliptin Benzoate, a potent DPP-4 inhibitor with >10,000-fold selectivity over DPP-8/9, may also curb TLR-4-induced inflammation.Formula:C25H27N5O4Purezza:99.94% - >99.99%Colore e forma:White PowderPeso molecolare:461.51Ref: ST-EA-CP-A13013
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiestaAlogliptin Benzoate
CAS:Applications Alogliptin Benzoate is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Alogliptin Benzoate is used in the treatment of type 2 diabetes.
References Wang, Y., et. al.: Drugs Future, 33, 7 (2008); Lynn, F., et al.: Diabetes, 50, 1004 (2001); Trumper, A., et al.: J. Endocrinol., 174, 233 (2002); Vollmer, K., et al.: J. Clin. Endocrinol. Metab., 94, 1379 (2009)Formula:C18H21N5O2·C7H6O2Colore e forma:NeatPeso molecolare:461.51Alogliptin benzoate
CAS:Alogliptin benzoate is an orally active DPP-IV inhibitor that is used for the treatment of type 2 diabetes. Alogliptin benzoate is a prodrug that is hydrolyzed to alogliptin in vivo, which binds to the DPP-IV enzyme and blocks it from degrading the incretin hormones, GLP-1 and GIP. These hormones are released by the ileum after a meal and act on pancreatic beta cells to release insulin. Alogliptin benzoate has been shown to improve glucose levels after a meal, while reducing postprandial glucagon levels, as well as improving insulin sensitivity in patients with type 2 diabetes mellitus. Alogliptin benzoate also reduces bowel disease symptoms such as abdominal pain, diarrhea, and constipation in patients with type 2 diabetes. The analytical method used for measuring alogliptin benzoate concentration in plasma or serum is chromatographic analysis with postpr
Formula:C18H21N5O2C7H6O2Purezza:Min. 95%Colore e forma:White PowderPeso molecolare:461.51 g/mol






